Overview

A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study in healthy volunteers, multiple dose study in patients with rheumatoid arthritis and multiple dose study in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Treatments:

Tofacitinib
Upadacitinib